Across TCGA pan-cancer cohorts, MYH1 mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated MYH1 data layer compared with 21 for mass-spec protein and 7 for mutation status.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher MYH1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated MYH1 expression acts as an unfavorable survival marker.
HNSC are the cancer types where MYH1 mass-spec protein most reproducibly stratifies survival.